 LA JOLLA, Calif, Aug. 03, 2020 GLOBE NEWSWIRE -- INmune Bio, Inc. NASDAQ: INMB the Company or INmune, a clinical-stage immunology company focused on developing treatments that harness a patients innate immune system to fight disease, today announced that management will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference being held August 10-11, 2020 and will also be available for 1x1 meetings. To schedule a meeting, please contact your BTIG representative or email INmune Bio Fireside Chat Details:BTIG Virtual Biotechnology Conference 2020 Date: Monday, August 10, 2020 Presentation Time: 1:00 - 1:25 PM ETAbout INmune Bio, Inc.INmune Bio, Inc. is a publicly traded NASDAQ: INMB, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications QuellorTM, cancer INB03TM, Alzheimers XPro595, and NASH LIVNateTM. The Natural Killer Cell Priming Platform includes INKmuneTM aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including without limitation statements regarding the completion and timing of the offering and the amount and use of proceeds therefrom, are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03TM, XPro1595, LIVNate, QuellorTM and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact: David Moss, CFO 858 964-3720 Contact: James Carbonara, Hayden IR 646 755-7412 